In the recent past, it has repeatedly been reported that CD4 cells play an important role in the immunology of chronic myeloid leukaemia. It was therefore of interest to test their activity in an animal model using bcr-abl-transformed cells. BALB/c mice were four times immunized with a DNA vaccine carrying the bcr-abl fusion gene. Two weeks after the last vaccine dose, the animals were challenged with syngeneic bcr-abl-transformed 12B1 cells which form solid tumors after subcutaneous administration. At the time of challenge, animals were treated with antibodies against the CD8+ T cells or CD4+ T cells. The efficacy of the depletion was monitored and found highly effective. All nonimmunized animals developed tumors. All animals untreated with the antibodies as well as those in which CD8+ T cells had been depleted, were fully protected against the challenge. On the other hand, almost all mice treated with anti-CD4+ antibody developed tumors. These results strongly suggested that the CD4+ T cells acted as effectors in the present system.

Institute of Hematology and Blood Transfusion Department of Experimental Virology U Nemocnice 1 12820 Prague 2 Czech Republic

Zobrazit více v PubMed

Kennedy R, Celis E. Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunological Reviews. 2008;222:129–144. PubMed

Thibodeau J, Bourgeois-Daigneault MC, Lapointe R. Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy. Oncoimmunology. 2012;1(6):908–916. PubMed PMC

Perez-Diez A, Joncker NT, Choi K, et al. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood. 2007;109(12):5346–5354. PubMed PMC

van de Berg PJ, van Leeuwen EM, ten Berge IJ, van Lier R. Cytotoxic human CD4+ T cells. Current Opinion in Immunology. 2008;20(3):339–343. PubMed

Appay V. The physiological role of cytotoxic CD4+ T-cells: the holy grail? Clinical and Experimental Immunology. 2004;138(1):10–13. PubMed PMC

Marshall NB, Swain SL. Cytotoxic CD4 T cells in antiviral immunity. Journal of Biomedicine and Biotechnology. 2011;2011954602 PubMed PMC

Namekawa T, Wagner UG, Goronzy JJ, Weyand CM. Functional subsets of CD4 T cells in rheumatoid synovitis. Arthritis and Rheumatism. 1998;41(12):2108–2116. PubMed

Porakishvili N, Kardava L, Jewell AP, et al. Cytotoxic CD4+ T cells in patients with B cell chronic lymphocytic leukemia kill via a perforin-mediated pathway. Haematologica. 2004;89(4):435–443. PubMed

Yasukawa M, Ohminami H, Arai J, Kasahara Y, Ishida Y, Fujita S. Granule exocytosis, and not the Fas/Fas ligand system, is the main pathway of cytotoxicity mediated by alloantigen-specific CD4+ as well as CD8+ cytotoxic T lymphocytes in humans. Blood. 2000;95(7):2352–2355. PubMed

Echchakir H, Bagot M, Dorothée G, et al. Cutaneous T cell lymphoma reactive CD4+ cytotoxic T lymphocyte clones display a Th1 cytokine profile and use a Fas-independent pathway for specific tumor cell lysis. Journal of Investigative Dermatology. 2000;115(1):74–80. PubMed

Lucansky V, Sobotkova E, Tachezy R, Duskova M, Vonka V. DNA vaccination against bcr-abl-positive cells in mice. International Journal of Oncology. 2009;35(4):941–951. PubMed

McLaughlin J, Chianese E, Witte ON. In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proceedings of the National Academy of Sciences of the United States of America. 1987;84(18):6558–6562. PubMed PMC

Petráčková M, Tachezy R, Vonka V. Properties of bcr-abl-transformed mouse 12B1 cells secreting interleukin-2 and granulocyte-macrophage colony-stimulating factor. I: derivation, genetic stability, oncogenicity and immunogenicity. International Journal of Oncology. 2012;40(5):1668–1676. PubMed

Šmahel M, Šíma P, Ludvíková V, Vonka V. Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells. Virology. 2001;281(2):231–238. PubMed

Aldrich JF, Lowe DB, Shearer MH, et al. CD4+ T lymphocytes are critical mediators of tumor immunity to simian virus 40 large tumor antigen induced by vaccination with plasmid DNA. Journal of Virology. 2011;85(14):7216–7224. PubMed PMC

Bright RK, Shearer MH, Kennedy RC. Immunization of BALB/c mice with recombinant simian virus 40 large tumor antigen induces antibody-dependent cell-mediated cytotoxicity against simian virus 40-transformed cells: an antibody-based mechanism for tumor immunity. Journal of Immunology. 1994;153(5):2064–2071. PubMed

Lowe DB, Shearer MH, Jumper CA, Bright RK, Kennedy RC. Tumor immunity against a simian virus 40 oncoprotein requires CD8 + T lymphocytes in the effector immune phase. Journal of Virology. 2010;84(2):883–893. PubMed PMC

Mumberg D, Monach PA, Wanderling S, et al. CD4+ T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ . Proceedings of the National Academy of Sciences of the United States of America. 1999;96(15):8633–8638. PubMed PMC

Hagn M, Sontheimer K, Dahlke K, et al. Human B cells differentiate into granzyme B-secreting cytotoxic B lymphocytes upon incomplete T-cell help. Immunology and Cell Biology. 2012;90(4):457–467. PubMed

Balsamo M, Pietra G, Vermi W, Moretta L, Mingari MC, Vitale M. Melanoma immunoediting by NK cells. Oncoimmunology. 2012;1(9):1607–1609. PubMed PMC

Fruci D, Lo ME, Cifaldi L, et al. T and NK cells: two sides of tumor immunoevasion. Journal of Translational Medicine. 2013;11, article 30 PubMed PMC

Serody JS, Brecher ME, Dent G, Bentley SA, Frelinger JA, Shea TC. A method for the production of CD4+ chronic myelogenous leukemia-specific allogeneic T lymphocytes. Cancer Research. 1997;57(8):1547–1553. PubMed

Jiang Y-Z, Mavroudis D, Dermime S, et al. Alloreactive CD4+ T lymphocytes can exert cytotoxicity to chronic myeloid leukaemia cells processing and presenting exogenous antigen. British Journal of Haematology. 1996;93(3):606–612. PubMed

Alyea EP, Soiffer RJ, Canning C, et al. Toxicity and efficacy of defined doses of CD4+ donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood. 1998;91(10):3671–3680. PubMed

Dodi I, Van Rhee F, Forde H, et al. CD4+ bias in T cells cloned from a CML patient with active graft versus leukemia effect. Cytotherapy. 2002;4(4):353–363. PubMed

Chen CL-U, Maecker HT, Lee PP. Development and dynamics of robust T-cell responses to CML under imatinib treatment. Blood. 2008;111(11):5342–5349. PubMed PMC

Ten Bosch GJA, Toornvliet AC, Friede T, Melief CJM, Leeksma OC. Recognition of peptides corresponding to the joining region of p210(BCR-ABL) protein by human T cells. Leukemia. 1995;9(8):1344–1348. PubMed

Yasukawa M, Ohminami H, Kaneko S, et al. CD4+ cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner. Blood. 1998;92(9):3355–3361. PubMed

Hirschhorn-Cymerman D, Budhu S, Kitano S, et al. Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype. Journal of Experimental Medicine. 2012;209(11):2113–2126. PubMed PMC